Get the Stockscreener App
1.255
3.46%
-0.045
Biomea Fusion Inc stock is traded at $1.255, with a volume of 337.31K.
It is down -3.46% in the last 24 hours and down -4.92% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.30
Open:
$1.31
24h Volume:
337.31K
Relative Volume:
0.25
Market Cap:
$88.46M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.313
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
-10.99%
1M Performance:
-4.92%
6M Performance:
-30.28%
1Y Performance:
-70.61%
1-Day Range:
$1.245
$1.32
1-Week Range:
$1.24
$1.4794
52-Week Range:
$0.8719
$4.43
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.2512 | 91.91M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.41 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.99 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
848.88 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
350.67 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.38 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Does Biomea Fusion Inc stock benefit from AI growth2025 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Market Catalysts: Is Biomea Fusion Inc part of any major indexJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Yahoo Finance
Levels Update: Does Biomea Fusion Inc offer margin of safetyQuarterly Performance Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Insider Monkey
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones - MarketBeat
BMEA: Durable A1C reduction and advancing weight loss studies highlight strong clinical momentum - TradingView
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference - TipRanks
Biomea Fusion, Inc. Updates on Icovamenib Clinical Progress - TradingView
Rodman & Renshaw Initiates Coverage on Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Rodman & Renshaw initiates Biomea Fusion stock with Buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates Biomea Fusion stock with Buy rating - Investing.com
BMEA: Today's Analyst Rating and Price Target Update | BMEA Stoc - GuruFocus
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital - MarketBeat
Published on: 2026-01-13 19:04:12 - Bộ Nội Vụ
Biomea Fusion outlines 2026 diabetes and obesity drug development plans By Investing.com - Investing.com Nigeria
Biomea Fusion outlines 2026 diabetes and obesity drug development plans - Investing.com
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - manilatimes.net
Experimental pills for diabetes and obesity line up key 2026 tests - Stock Titan
Biomea Fusion launches public offering of stock and warrants; shares down 23% - MSN
Is Biomea Fusion Inc. stock near bottom after decline2025 Market Outlook & AI Driven Stock Reports - ulpravda.ru
Stop Loss: Is Biomea Fusion Inc. stock near bottom after declineDollar Strength & Advanced Swing Trade Entry Alerts - Улправда
Will Biomea Fusion Inc. stock return to pre crisis levels2026 world cup usa national team round of 16 key players build up play expert forecast preview - ulpravda.ru
Biomea Fusion looks to major milestones in 2026 - Traders Union
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Biomea Fusion Inc. (BMEA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion explores challenges of insulin therapy - Traders Union
Can Biomea Fusion Inc. stock outperform in 2025 bull marketCEO Change & Detailed Earnings Play Strategies - Улправда
Published on: 2025-12-20 18:19:39 - Улправда
How interest rate cuts could boost Biomea Fusion Inc. stockWeekly Stock Recap & Daily Momentum Trading Reports - Улправда
Published on: 2025-12-20 15:52:57 - Улправда
Will Biomea Fusion Inc. stock split attract more investors2025 Technical Overview & Technical Entry and Exit Alerts - DonanımHaber
Published on: 2025-12-19 02:18:12 - Улправда
Aug Closing: Will Biomea Fusion Inc. stock outperform growth indexesJuly 2025 Action & Risk Controlled Swing Alerts - Улправда
Gap Down: Can Biomea Fusion Inc. stock outperform in 2025 bull market - Улправда
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from NASDAQ Biotechnology Index - marketscreener.com
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Insider Buying: Biomea Fusion (NASDAQ:BMEA) Insider Acquires 30,000 Shares of Stock - MarketBeat
Biomea Fusion Director Rainer M Erdtmann Acquires 30,000 Shares - TradingView — Track All Markets
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Biomea F - GuruFocus
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.70%
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):